Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 12/20 | 0.50 |
| ▸ | FLT1 | P17948 | 10/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCND3 | P30281 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538820 | 1.00 | FGFR1 (0.50) | FGFR1FLT1KDRCHEK1PDPK1 | |
| SCHEMBL3533656 | 1.00 | FGFR1 (0.50) | FGFR1FLT1KDRCHEK1PDPK1 | |
| SCHEMBL3533658 | 1.00 | FGFR1 (0.50) | FGFR1FLT1KDRCHEK1PDPK1 | |
| SCHEMBL3540557 | 1.00 | FGFR1 (0.50) | FGFR1FLT1KDRCHEK1PDPK1 | |
| SCHEMBL3535767 | 0.94 | FGFR1 (0.43) | FGFR1FLT1KDRCHEK1PDPK1 | |
| SCHEMBL3543592 | 0.91 | FGFR1 (0.49) | FGFR1FLT1KDRCHEK1PDPK1 | |
| SCHEMBL3535097 | 0.91 | CHEK1 (0.41) | FGFR1FLT1KDRCHEK1PDPK1 | |
| SCHEMBL3537769 | 0.91 | FGFR1 (0.49) | FGFR1FLT1KDRCHEK1PDPK1 | |
| SCHEMBL3538106 | 0.91 | CHEK1 (0.41) | FGFR1FLT1KDRCHEK1PDPK1 | |
| SCHEMBL3538304 | 0.91 | CHEK1 (0.41) | FGFR1FLT1KDRCHEK1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | FGFR1 886/4885FLT1 2793/4885KDR 2852/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | FGFR1 2175/4885FLT1 3562/4885KDR 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.